Irritable Bowel Syndrome  >>  Xifaxan (rifaximin)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health
TARGET3 , NCT01543178 / 2013-002394-22: Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study

Completed
3
2583
US, Europe
open-label rifaximin, rifaximin, double-blind placebo, Placebo, double-blind rifaximin
Bausch Health Americas, Inc.
Irritable Bowel Syndrome With Diarrhea
06/14
06/14

Download Options